Literature DB >> 7979288

L-651,392, a potent leukotriene inhibitor, controls inflammatory process in Escherichia coli pyelonephritis.

M Tardif1, D Beauchamp, Y Bergeron, C Lessard, P Gourde, M G Bergeron.   

Abstract

In this study, the relationship between leukotrienes, peritubular cell infiltration with polymorphonuclear cells (PMNs) and renal tubular damage was investigated in a rat model of acute ascending pyelonephritis. Infection was induced by the injection of 10(5) CFU of Escherichia coli into the bladder and occlusion of the left ureter for 24 h. Treatment of infected animals was started 24 h after the induction of pyelonephritis with either hydrocortisone (25 mg/kg of body weight per day), the leukotriene inhibitor L-651,392 (10 mg/kg/day), or the vehicle of L-651,392 and was maintained for 5 days. At the end of treatment, the animals were killed, serum was collected, and both kidneys were removed for colony counts and histopathology. Renal function was evaluated by the measurement of blood urea nitrogen levels and creatinine clearance. The numbers of PMNs and mononuclear cells (MNs) in the cortex and medulla were recorded for all groups on plastic sections done from the left kidney. Infection alone (vehicle of L-651,392) resulted in intensive interstitial infiltration and a severe tubular destruction in the cortex. Treatment with hydrocortisone did not prevent PMN migration and tissue damage. By contrast, treatment with L-651,392 resulted in a significant reduction in PMNs (P < 0.001 in comparisons with all other groups) and greater preservation of the tubular structure despite identical bacterial counts than in the group receiving hydrocortisone. We conclude that L-651,392 prevents inflammatory cells from reaching the site of infection and protects the kidney from tubular damage associated with inflammation during pyelonephritis. Inhibitors of leukotrienes should be further investigated for their potential benefit as adjuvants to antibiotherapy in the treatment of pyelonephritis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7979288      PMCID: PMC284592          DOI: 10.1128/AAC.38.7.1555

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Immunology of pyelonephritis in the primate model. VI. Effect of complement depletion.

Authors:  J A Roberts; J K Roth; G Domingue; R W Lewis; B Kaack; G Baskin
Journal:  J Urol       Date:  1983-01       Impact factor: 7.450

Review 2.  Corticosteroid-induced changes in phospholipid membranes as mediators of their action.

Authors:  D H Nelson
Journal:  Endocr Rev       Date:  1980       Impact factor: 19.871

3.  Prevention of chronic experimental pyelonephritis by suppression of acute suppuration.

Authors:  M P Glauser; J M Lyons; A I Braude
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

4.  Significance of intrarenal concentrations of gentamicin for the outcome of experimental pyelonephritis in rats.

Authors:  M G Bergeron; A Bastille; C Lessard; P M Gagnon
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

5.  Protection against chronic pyelonephritis in rats by suppression of acute suppuration: effect of colchicine and neutropenia.

Authors:  J Bille; M P Glauser
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

6.  Disturbed intrarenal distribution of gentamicin in experimental pyelonephritis due to Escherichia coli.

Authors:  M G Bergeron; S Trottier; C Lessard; D Beauchamp; P M Gagnon
Journal:  J Infect Dis       Date:  1982-09       Impact factor: 5.226

7.  Failure of dexamethasone to prevent polymorphonuclear leukocyte infiltration during experimental acute exudative pyelonephritis and to reduce subsequent chronic scarring.

Authors:  P R Meylan; M P Glauser
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

8.  Effect of indomethacin on the incidence of experimental Escherichia coli pyelonephritis.

Authors:  M P Glauser; P B Francioli; J Bille; M Bonard; P Meylan
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

9.  Immunology of pyelonephritis in the primate model. V. Effect of superoxide dismutase.

Authors:  J A Roberts; J K Roth; G Domingue; R W Lewis; B Kaack; G Baskin
Journal:  J Urol       Date:  1982-12       Impact factor: 7.450

10.  Pyelonephritis: the relationship between infection, renal scarring, and antimicrobial therapy.

Authors:  T Miller; S Phillips
Journal:  Kidney Int       Date:  1981-05       Impact factor: 10.612

View more
  3 in total

1.  Flavocoxid attenuates gentamicin-induced nephrotoxicity in rats.

Authors:  Dalia H El-Kashef; Asmaa E El-Kenawi; Ghada M Suddek; Hatem A Salem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-15       Impact factor: 3.000

2.  [Nephrectomy in acute uncomplicated pyelonephritis].

Authors:  H-J Knopf; H Schulze
Journal:  Urologe A       Date:  2004-11       Impact factor: 0.639

3.  The role of dexamethasone on decreasing urinary cytokines in children with acute pyelonephritis.

Authors:  Mostafa Sharifian; Navid Anvaripour; Abdollah Karimi; Alireza Fahimzad; Masoomeh Mohkam; Reza Dalirani; Fatemeh Gholikhani; Mohammad Ali Rafiee
Journal:  Pediatr Nephrol       Date:  2008-06-13       Impact factor: 3.714

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.